Optimizing randomized trial designs to distinguish which subpopulations benefit from treatment
DOI10.1093/BIOMET/ASR055zbMATH Open1228.62148OpenAlexW2094133309WikidataQ36145026 ScholiaQ36145026MaRDI QIDQ3107976FDOQ3107976
Authors: Michael Rosenblum, Mark J. Van der Laan 
Publication date: 28 December 2011
Published in: Biometrika (Search for Journal in Brave)
Full work available at URL: http://europepmc.org/articles/pmc3413180
Recommendations
- On optimal subset designs for phase II clinical trials with both total response and disease control
- Optimizing parameters in clinical trials with a randomized start or withdrawal design
- Robustifying trial-derived optimal treatment rules for a target population
- Optimal designs for dose-escalation trials and individual allocations in cohorts
- An Optimal Design for Screening Trials
- Optimal adaptive randomized designs for clinical trials
- Efficient design for clinically relevant intent-to-treat comparisons
Applications of statistics to biology and medical sciences; meta analysis (62P10) Medical applications (general) (92C50) Sequential statistical design (62L05)
Cited In (13)
- Analysis of ``learn-as-you-go (LAGO) studies
- Adaptive patient enrichment designs in therapeutic trials
- Adaptive randomized trial designs that cannot be dominated by any standard design at the same total sample size
- Recursive partitioning for heterogeneous causal effects
- Special study designs: early escape, enrichment, studies in non-responders
- Random norming AIDS analysis of non-linear regression models with sequential informative dose selection
- New insights into adaptive enrichment designs
- Uniformly most powerful tests for simultaneously detecting a treatment effect in the overall population and at least one subpopulation
- A predictive enrichment procedure to identify potential responders to a new therapy for randomized, comparative controlled clinical studies
- Inference for a two-stage enrichment design
- Confidence intervals for the selected population in randomized trials that adapt the population enrolled
- Optimal tests of treatment effects for the overall population and two subpopulations in randomized trials, using sparse linear programming
- Optimal treatments in cost-effectiveness analysis in the presence of covariates: improving patient subgroup definition
This page was built for publication: Optimizing randomized trial designs to distinguish which subpopulations benefit from treatment
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q3107976)
